Identification of functionally important amino acid sequences in cobra venom factor using human C3/Cobra venom factor hybrid proteins. 2019

Brian E Hew, and David C Fritzinger, and Michael K Pangburn, and Carl-Wilhelm Vogel
University of Hawaii Cancer Center, University of Hawaii at Manoa, 701 Ilalo Street, Honolulu, HI, 96813, USA.

Cobra venom factor (CVF) is the complement-activating protein in cobra venom. CVF is a structural and functional analog of complement component C3. CVF, like C3b, forms a convertase with factor B. This bimolecular complex CVF,Bb is an enzyme that cleaves C3 and C5. However, CVF,Bb exhibits significantly different functional properties from C3b,Bb. The CVF,Bb convertase is physico-chemically very stable, and completely resistant to an activation by Factors H and I. These two properties, in contrast to C3b,Bb, allow continuous activation of C3 and C5, and complement depletion in serum. In order to understand the structural basis for the functional differences between CVF and C3, we have created several hybrid proteins of CVF and human C3. Here we report that replacing the C-terminal 168 amino acid residues of human C3 with the corresponding residues from CVF results in a hybrid protein (HC3-1496) which is essentially a human C3 derivative exhibiting the functional properties of CVF. This result demonstrates that the important structures for the CVF-specific functions reside within the C-terminal 168 amino acid residues of CVF. We further demonstrate that reverting the 46 C-terminal CVF residues of HC3-1496 to human C3 sequence results in a hybrid protein (HC3-1496/1617) that exhibits a physico-chemically unstable convertase with only residual complement depleting activity. This result demonstrates that most, but not all, structural requirements for CVF activity reside within the 46 C-terminal amino acid residues. We also investigated the potential role of position 1633, which is an acidic residue in human C3 (glutamic acid) but a basic amino acid residue (histidine) in CVF. However, the charge at position 1633 appears to be of no functional relevance. Exchanging the neutral amino acids present in CVF at positions 1499 and 1501 with the two charged amino acids at these positions in human C3 (aspartic acid and lysine) resulted in a hybrid protein that exhibited significantly slower convertase formation although both binding to Factor B and C3 cleavage was not affected, demonstrating that the charged amino acid residues at these two positions interfere with the formation of the convertase. In conclusion, our work demonstrates that hybrid proteins of human C3 and CVF present valuable tools to identify functionally important amino acid residues in CVF.

UI MeSH Term Description Entries
D011993 Recombinant Fusion Proteins Recombinant proteins produced by the GENETIC TRANSLATION of fused genes formed by the combination of NUCLEIC ACID REGULATORY SEQUENCES of one or more genes with the protein coding sequences of one or more genes. Fusion Proteins, Recombinant,Recombinant Chimeric Protein,Recombinant Fusion Protein,Recombinant Hybrid Protein,Chimeric Proteins, Recombinant,Hybrid Proteins, Recombinant,Recombinant Chimeric Proteins,Recombinant Hybrid Proteins,Chimeric Protein, Recombinant,Fusion Protein, Recombinant,Hybrid Protein, Recombinant,Protein, Recombinant Chimeric,Protein, Recombinant Fusion,Protein, Recombinant Hybrid,Proteins, Recombinant Chimeric,Proteins, Recombinant Fusion,Proteins, Recombinant Hybrid
D003176 Complement C3 A glycoprotein that is central in both the classical and the alternative pathway of COMPLEMENT ACTIVATION. C3 can be cleaved into COMPLEMENT C3A and COMPLEMENT C3B, spontaneously at low level or by C3 CONVERTASE at high level. The smaller fragment C3a is an ANAPHYLATOXIN and mediator of local inflammatory process. The larger fragment C3b binds with C3 convertase to form C5 convertase. C3 Complement,C3 Precursor,Complement 3,Complement C3 Precursor,Complement Component 3,Precursor-Complement 3,Pro-C3,Pro-Complement 3,C3 Precursor, Complement,C3, Complement,Complement, C3,Component 3, Complement,Precursor Complement 3,Precursor, C3,Precursor, Complement C3,Pro C3,Pro Complement 3
D004546 Elapid Venoms Venoms from snakes of the family Elapidae, including cobras, kraits, mambas, coral, tiger, and Australian snakes. The venoms contain polypeptide toxins of various kinds, cytolytic, hemolytic, and neurotoxic factors, but fewer enzymes than viper or crotalid venoms. Many of the toxins have been characterized. Cobra Venoms,Elapidae Venom,Elapidae Venoms,Naja Venoms,Cobra Venom,Elapid Venom,Hydrophid Venom,Hydrophid Venoms,King Cobra Venom,Naja Venom,Ophiophagus hannah Venom,Sea Snake Venom,Sea Snake Venoms,Venom, Cobra,Venom, Elapid,Venom, Elapidae,Venom, Hydrophid,Venom, King Cobra,Venom, Naja,Venom, Ophiophagus hannah,Venom, Sea Snake,Venoms, Cobra,Venoms, Elapid,Venoms, Elapidae,Venoms, Hydrophid,Venoms, Naja,Venoms, Sea Snake
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000595 Amino Acid Sequence The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION. Protein Structure, Primary,Amino Acid Sequences,Sequence, Amino Acid,Sequences, Amino Acid,Primary Protein Structure,Primary Protein Structures,Protein Structures, Primary,Structure, Primary Protein,Structures, Primary Protein
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D020539 Sequence Analysis, Protein A process that includes the determination of AMINO ACID SEQUENCE of a protein (or peptide, oligopeptide or peptide fragment) and the information analysis of the sequence. Amino Acid Sequence Analysis,Peptide Sequence Analysis,Protein Sequence Analysis,Sequence Determination, Protein,Amino Acid Sequence Analyses,Amino Acid Sequence Determination,Amino Acid Sequence Determinations,Amino Acid Sequencing,Peptide Sequence Determination,Protein Sequencing,Sequence Analyses, Amino Acid,Sequence Analysis, Amino Acid,Sequence Analysis, Peptide,Sequence Determination, Amino Acid,Sequence Determinations, Amino Acid,Acid Sequencing, Amino,Analyses, Peptide Sequence,Analyses, Protein Sequence,Analysis, Peptide Sequence,Analysis, Protein Sequence,Peptide Sequence Analyses,Peptide Sequence Determinations,Protein Sequence Analyses,Protein Sequence Determination,Protein Sequence Determinations,Sequence Analyses, Peptide,Sequence Analyses, Protein,Sequence Determination, Peptide,Sequence Determinations, Peptide,Sequence Determinations, Protein,Sequencing, Amino Acid,Sequencing, Protein

Related Publications

Brian E Hew, and David C Fritzinger, and Michael K Pangburn, and Carl-Wilhelm Vogel
August 1987, Journal of immunology (Baltimore, Md. : 1950),
Brian E Hew, and David C Fritzinger, and Michael K Pangburn, and Carl-Wilhelm Vogel
February 2000, Biochemistry,
Brian E Hew, and David C Fritzinger, and Michael K Pangburn, and Carl-Wilhelm Vogel
July 1973, Biochimica et biophysica acta,
Brian E Hew, and David C Fritzinger, and Michael K Pangburn, and Carl-Wilhelm Vogel
June 1971, Die Naturwissenschaften,
Brian E Hew, and David C Fritzinger, and Michael K Pangburn, and Carl-Wilhelm Vogel
May 2004, Molecular immunology,
Brian E Hew, and David C Fritzinger, and Michael K Pangburn, and Carl-Wilhelm Vogel
October 1983, Journal of immunology (Baltimore, Md. : 1950),
Brian E Hew, and David C Fritzinger, and Michael K Pangburn, and Carl-Wilhelm Vogel
June 1972, Japanese journal of medical science & biology,
Brian E Hew, and David C Fritzinger, and Michael K Pangburn, and Carl-Wilhelm Vogel
August 1969, Biochemical and biophysical research communications,
Brian E Hew, and David C Fritzinger, and Michael K Pangburn, and Carl-Wilhelm Vogel
May 2005, Hawaii medical journal,
Brian E Hew, and David C Fritzinger, and Michael K Pangburn, and Carl-Wilhelm Vogel
October 2002, Journal of biochemistry,
Copied contents to your clipboard!